TELO - Telomir Pharmaceuticals Inc Market Cap to Sales Volume

Corporate company logo of Telomir Pharma (TELO)

Telomir Pharmaceuticals relies on partnerships with clinics to develop anti-aging formulas. This P/S multiple chart visualizes the market reaction to these alliances, where determines the latest valuation metric. The absence of commercial sales leaves the company dependent on investor capital, although ambitions in cellular rejuvenation and the fight against tissue degeneration sustain high interest from the scientific community.

TELO telomirpharma.com Price-to-Revenue Ratio (07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for telomirpharma.com (TELO)

- share price and consensus valuation forecast:
General company analysis:TELO, Telomir Pharmaceuticals Inc
Mass-produced product of Telomir Pharmaceuticals

The scale of Telomir Pharmaceuticals (TELO) business is clearly reflected in the P/S fluctuation, which links market capitalization to sales volume. This multiple measures the value of each unit of revenue, demonstrating the company's ability to pass inflationary costs onto consumers. For a drug developer, this calculation is critical, as geopolitical risks and sanctions directly impact the stability of component supplies. An increasing ratio signals investor confidence, yet creates a risk of correction should clinical trials fail.

Competitors of Telomir Pharmaceuticals

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue Ratio HYFT|ABVC (ABVC BioPharma, Inc) - P/S Multiple|P/S Multiple cumberlandpharma.com|Price-to-Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Price-to-Revenue Multiple|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)